{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,9]],"date-time":"2025-11-09T03:50:34Z","timestamp":1762660234656},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,5,18]],"date-time":"2022-05-18T00:00:00Z","timestamp":1652832000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,5,18]],"date-time":"2022-05-18T00:00:00Z","timestamp":1652832000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Access to a comprehensive molecular alteration screening is patchy in Europe and quality of the molecular analysis varies. SPECTAlung was created in 2015 as a pan-European screening platform for patients with thoracic malignancies. Here we report the results of almost 4\u00a0years of prospective molecular screening of patients with thoracic malignancies, in terms of quality of the program and molecular alterations identified. Patients with thoracic malignancies at any stage of disease were recruited in SPECTAlung, from June 2015 to May 2019, in 7 different countries. Molecular tumour boards were organised monthly to discuss patients\u2019 molecular and clinical profile and possible biomarker-driven treatments, including clinical trial options. FFPE material was collected and analysed for 576 patients with diagnosis of pleural, lung, or thymic malignancies. Ultimately, 539 patients were eligible (93.6%) and 528 patients were assessable (91.7%). The turn-around time for report generation and molecular tumour board was 214\u00a0days (median). Targetable molecular alterations were observed in almost 20% of cases, but treatment adaptation was low (3% of patients). SPECTAlung showed the feasibility of a pan-European screening platform. One fifth of the patients had a targetable molecular alteration. Some operational issues were discovered and adapted to improve efficiency.<\/jats:p>","DOI":"10.1038\/s41598-022-12056-0","type":"journal-article","created":{"date-parts":[[2022,5,18]],"date-time":"2022-05-18T19:26:32Z","timestamp":1652901992000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Results of screening in early and advanced thoracic malignancies in the EORTC pan-European SPECTAlung platform"],"prefix":"10.1038","volume":"12","author":[{"given":"M.","family":"Morfouace","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Novello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Stevovic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Dooms","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"U.","family":"Jan\u017ei\u010d","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Berghmans","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Dziadziuszko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Gorlia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Felip","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Paz-Ares","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Mazieres","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"O\u2019Brien","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Bironzo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Vansteenkiste","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Lacroix","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. C.","family":"Dingemans","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Golfinopoulos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Besse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,5,18]]},"reference":[{"key":"12056_CR1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","author":"H Sung","year":"2021","unstructured":"Sung, H. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. https:\/\/doi.org\/10.3322\/caac.21660 (2021).","journal-title":"CA Cancer J. Clin."},{"key":"12056_CR2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.33588","author":"J Ferlay","year":"2021","unstructured":"Ferlay, J. et al. Cancer statistics for the year 2020: An overview. Int. J. Cancer https:\/\/doi.org\/10.1002\/ijc.33588 (2021).","journal-title":"Int. J. Cancer"},{"key":"12056_CR3","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21654","author":"RL Siegel","year":"2021","unstructured":"Siegel, R. L., Miller, K. D., Fuchs, H. E. & Jemal, A. Cancer Statistics, 2021. CA Cancer J. Clin. https:\/\/doi.org\/10.3322\/caac.21654 (2021).","journal-title":"CA Cancer J. Clin."},{"key":"12056_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2021.02.026","author":"KM Kerr","year":"2021","unstructured":"Kerr, K. M. et al. The evolving landscape of biomarker testing for non-small cell lung cancer in Europe. Lung Cancer https:\/\/doi.org\/10.1016\/j.lungcan.2021.02.026 (2021).","journal-title":"Lung Cancer"},{"key":"12056_CR5","doi-asserted-by":"publisher","DOI":"10.1038\/ng.3564","author":"JD Campbell","year":"2016","unstructured":"Campbell, J. D. et al. Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas. Nat. Genet. https:\/\/doi.org\/10.1038\/ng.3564 (2016).","journal-title":"Nat. Genet."},{"key":"12056_CR6","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-16-1337","author":"EJ Jordan","year":"2017","unstructured":"Jordan, E. J. et al. Prospective comprehensive molecular characterization of lung adenocarcinomas for efficient patient matching to approved and emerging therapies. Cancer Discov. https:\/\/doi.org\/10.1158\/2159-8290.CD-16-1337 (2017).","journal-title":"Cancer Discov."},{"key":"12056_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2018.03.022","author":"KA Hoadley","year":"2018","unstructured":"Hoadley, K. A. et al. Cell-of-Origin patterns dominate the molecular classification of 10,000 tumors from 33 types of cancer. Cell https:\/\/doi.org\/10.1016\/j.cell.2018.03.022 (2018).","journal-title":"Cell"},{"key":"12056_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.canep.2015.02.003","author":"E Esteban","year":"2015","unstructured":"Esteban, E. et al. Prevalence of EGFR mutations in newly diagnosed locally advanced or metastatic non-small cell lung cancer Spanish patients and its association with histological subtypes and clinical features: The Spanish REASON study. Cancer Epidemiol. https:\/\/doi.org\/10.1016\/j.canep.2015.02.003 (2015).","journal-title":"Cancer Epidemiol."},{"key":"12056_CR9","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.12587","author":"YL Zhang","year":"2016","unstructured":"Zhang, Y. L. et al. The prevalence of EGFR mutation in patients with non-small cell lung cancer: A systematic review and meta-analysis. Oncotarget https:\/\/doi.org\/10.18632\/oncotarget.12587 (2016).","journal-title":"Oncotarget"},{"key":"12056_CR10","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e318290868f","author":"NI Lindeman","year":"2013","unstructured":"Lindeman, N. I. et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Patho. J. Thorac. Oncol. https:\/\/doi.org\/10.1097\/JTO.0b013e318290868f (2013).","journal-title":"J. Thorac. Oncol."},{"key":"12056_CR11","doi-asserted-by":"publisher","DOI":"10.1179\/0001551214Z.00000000029","author":"A Janssens","year":"2014","unstructured":"Janssens, A. et al. Routine implementation of EGFR mutation testing in clinical practice in Flanders: \u2018HERMES\u2019 project. Acta Clin. Belg. https:\/\/doi.org\/10.1179\/0001551214Z.00000000029 (2014).","journal-title":"Acta Clin. Belg."},{"key":"12056_CR12","doi-asserted-by":"publisher","DOI":"10.1007\/s00428-008-0689-3","author":"S Dacic","year":"2008","unstructured":"Dacic, S. et al. Prognostic significance of p16\/cdkn2a loss in pleural malignant mesotheliomas. Virchows Arch. https:\/\/doi.org\/10.1007\/s00428-008-0689-3 (2008).","journal-title":"Virchows Arch."},{"key":"12056_CR13","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.10923","author":"PB Illei","year":"2003","unstructured":"Illei, P. B., Ladanyi, M., Rusch, V. W. & Zakowski, M. F. The use of CDKN2A deletion as a diagnostic marker for malignant mesothelioma in body cavity effusions. Cancer https:\/\/doi.org\/10.1002\/cncr.10923 (2003).","journal-title":"Cancer"},{"key":"12056_CR14","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.603223","author":"E Dudnik","year":"2021","unstructured":"Dudnik, E. et al. BAP1-altered malignant pleural mesothelioma: outcomes with chemotherapy, immune check-point inhibitors and poly(ADP-Ribose) polymerase inhibitors. Front. Oncol. https:\/\/doi.org\/10.3389\/fonc.2021.603223 (2021).","journal-title":"Front. Oncol."},{"key":"12056_CR15","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2020-001075","author":"M Morfouace","year":"2020","unstructured":"Morfouace, M. et al. First results of the EORTC-SPECTA\/Arcagen study exploring the genomics of rare cancers in collaboration with the European reference network EURACAN. ESMO Open https:\/\/doi.org\/10.1136\/esmoopen-2020-001075 (2020).","journal-title":"ESMO Open"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-12056-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-12056-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-12056-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,25]],"date-time":"2022-11-25T03:05:02Z","timestamp":1669345502000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-12056-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,18]]},"references-count":15,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["12056"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-12056-0","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,18]]},"assertion":[{"value":"8 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 April 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Dr. Morfouace, A. Stevovic, Dr. Gorlia, Dr. Golfinopoulos, Dr. Dooms, Dr. Jan\u017ei\u010d, Dr. Berghmans, Dr. O\u2019Brien, Dr. Bironzo, Dr. Vansteenkiste and Dr. Lacroix declare no competing interests. Dr. MAZIERES reports: Personal fees from Roche, Astra Zeneca, Pierre Fabre, Takeda, BMS, MSD, Jiangsu Hengrui, Blueprint, Daiichi, Novartis, Amgen. Grants from Roche, Astra Zeneca, Pierre Fabre, BMS. Dr. DINGEMANS reports: Attending advisory boards and\/or provided lectures for: Roche, Eli Lilly, Boehringer Ingelheim, Astra Zeneca, Pfizer, BMS, Amgen, Novartis, MSD, Takeda, Pharmamar. Receiving research support from BMS, AbbVie, Amgen (all paid to her institute). Dr. NOVELLO reports: Being an advisor\/Speaker bureau: AZ, AMG, BI, Beigene, MSD, Eli Lilly, Roche, Takeda, Pfizer, Roche, Sanofi, Novartis. Dr. FELIP reports: Advisory Role or Speaker\u2019s Bureau: Amgen, Astra Zeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, F. Hoffmann-La Roche, Glaxo Smith Kline, Janssen, Medscape, Merck KGaA, Merck Sharp & Dohme, Novartis, Peptomyc, PeerVoice, Pfizer, Regeneron, Sanofi Genzyme, Syneos Health, Seattle Genetics, Takeda, Touch Medical. Board member: Grifols, Independent member. Research Funding: Fundaci\u00f3n Merck Salud, Grant for Oncology Innovation, Merck Healthcare KGaA. Dr. PAZ-ARES reports: Grants or contracts from any entity: MSD, Astrazeneca, Pfizer, BMS. Consulting fees: Lilly, MSD, Roche, Pharmamar, Merck, Astrazeneca, Novartis, Servier, Amgen, Pfizer, Ipsen, Sanofi, Bayer, Blueprint, BMS, Mirati. Payment or honoraria for lectures, presentations, speaker bureaus, manuscript writing or educational events: Astrazeneca, Janssen, Merck, Mirati, Sanofi. Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid: Genomica, Altum sequency. Dr. DZIADZUSZKO reports: Advisory role\/compensated: AstraZeneca, Roche, Novartis, MSD, Pfizer, Boehringer Ingelheim, FoundationMedicine, Karyopharm, Takeda. Dr. BESSE reports: Sponsored Research at Gustave Roussy Cancer Center: 4D Pharma, Abbvie, Amgen, Aptitude Health, AstraZeneca, BeiGene, Blueprint Medicines, BMS, Boehringer Ingelheim, Celgene, Cergentis, Cristal Therapeutics, Daiichi-Sankyo, Eli Lilly, GSK, Inivata, Janssen, Onxeo, OSE immunotherapeutics, Pfizer, Roche-Genentech, Sanofi, Takeda, Tolero Pharmaceuticals.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"8342"}}